Geneva, Switzerland (PRWEB) April 26, 2012
Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the Company’s chief technology officer, Armelle Gaussin, PhD, will be speaking on Designer Cell Lines for Difficult-to-Express Proteins at the 2012 PEGS Summit on Wednesday, May 2, 2012 at the Boston Park Plaza Hotel & Towers in Boston, Massachusetts. Selexis will also be exhibiting at the conference, April 30 – May 4, 2012.
Dr. Gaussin’s lecture, “Developing the Next Generation Designer Cell Lines as a Customized Approach for Optimized Therapeutic Protein Production” is part of the Engineering Antibodies track. Conference attendees can hear Dr. Gaussin’s lecture on Wednesday, May 2 at 11:40 AM.
The Chinese Hamster Ovary cell line is the predominant host for the production of therapeutic proteins. However, its capacity to provide high levels of certain classes of products such as fusion proteins remains limited. In order to overcome the specific expression bottlenecks associated with these difficult-to-express proteins, we have developed new designer CHO cell lines. These next generation cell lines have been metabolically engineered to over-express key components of the cell secretion network.
Additionally, conference attendees can meet Selexis representatives at Booth 7, April 30 – May 4. To schedule meetings in advance, please contact Selexis at SURE(at)selexis(dot)com.
Registration for the PEGS conference is required. For more information, visit http://www.pegsummit.com/
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.
For more information: